
|Articles|January 10, 2005
Implant provides long-acting treatment for prostate cancer
Luteinizing hormone-releasing hormone (LHRH) agonists are a mainstay in treating locally advanced and metastatic prostate cancer, with the U.S. market for these therapies representing more than $1 billion in annual sales. The market is dominated by four-month and shorter depot injections and implants, such as leupro-lide acetate (Lupron, TAP Pharmaceuticals) for depot suspension and goserelin acetate (Zoladex, Astra Zeneca) implant.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Expands Approval of Flibanserin for Postmenopausal Women’s Sexual Health
2
Why Trump’s Second Term is Different for the MFN Drug Pricing Policy
3
Pharmacists Can Play Central Role in Patients’ Infusion Services | ASHP Midyear 2025
4
Taking Care of Every Patient in Every Pharmacy
5




























































































































